de Seze O - Search Results

1

[Neutralization of a very low molecular weight heparin fraction CY 222 by protamine. In vitro and in vivo study].

Doutremepuich C, Bonini F, de Seze O, Toulemonde F, Bayrou B. Doutremepuich C, et al. Among authors: de seze o. Therapie. 1986 Nov-Dec;41(6):433-6. Therapie. 1986. PMID: 3810539 French. No abstract available.

2

Influence of heparin and a low molecular weight heparin fraction of the leukocytes in an experimental venous thrombosis model.

Doutremepuich C, Toulemonde F, de Seze O, Pereira F, Anne MC, Doutremepuich F. Doutremepuich C, et al. Among authors: de seze o. J Leukoc Biol. 1987 Dec;42(6):628-31. doi: 10.1002/jlb.42.6.628. J Leukoc Biol. 1987. PMID: 2824648

3

Role of bone marrow in the development of thrombosis. A study of the curative and prophylactic action of heparin and heparin fragment (CY 222).

Doutremepuich C, Guyot M, Doutremepuich F, De Seze O, Masse A, Toulemonde F. Doutremepuich C, et al. Among authors: de seze o. Thromb Res. 1989 May 15;54(4):369-75. doi: 10.1016/0049-3848(89)90095-9. Thromb Res. 1989. PMID: 2548301 No abstract available.

4

What is the best plasmatic activity which could be correlated with the antithrombotic effect of heparin and a low molecular weight heparin fragment?

Doutremepuich C, Castrioto T, De Seze O, Pereira F, Doutremepuich F, Anne MC, Toulemonde F. Doutremepuich C, et al. Among authors: de seze o. Thromb Res. 1987 Oct 15;48(2):245-51. doi: 10.1016/0049-3848(87)90421-x. Thromb Res. 1987. PMID: 2827341 No abstract available.

5

[Potentiation by heparins of the action of leukocytes in experimental venous thrombosis].

Doutremepuich C, de Seze O, Lalanne MC, Doutremepuich F, Toulemonde F. Doutremepuich C, et al. Among authors: de seze o. Ann Pharm Fr. 1988;46(3):197-203. Ann Pharm Fr. 1988. PMID: 2851957 French. No abstract available.

6

The tPA-like activity induced by heparin and a heparin fragment binds on experimental thrombus.

Doutremepuich C, Toulemonde F, Doutremepuich F, de Sèze O, Bayrou B, Pereira F. Doutremepuich C, et al. Among authors: de seze o. Thromb Res. 1988 Apr 15;50(2):335-8. doi: 10.1016/0049-3848(88)90235-6. Thromb Res. 1988. PMID: 3134740 No abstract available.

7

What is the effect of acetylsalicylic acid at ultra low dose on the interaction platelets/vessel wall?

Lalanne MC, Doutremepuich C, de Sèze O, Belon P. Lalanne MC, et al. Among authors: de seze o. Thromb Res. 1990 Nov 1;60(3):231-6. doi: 10.1016/0049-3848(90)90184-e. Thromb Res. 1990. PMID: 2084952 No abstract available.

8

[How to standardize low molecular weight heparins].

Doutremepuich C, Puyal C, Lalanne MC, Doutremepuich F, De Sèze O. Doutremepuich C, et al. Among authors: de seze o. Ann Biol Clin (Paris). 1990;48(4):221-5. Ann Biol Clin (Paris). 1990. PMID: 2163227 Review. French.

9

Laboratory control of heparin and heparin fragment treatment: an experimental study.

Doutremepuich C, Lalanne MC, Guyot M, Doutremepuich F, De Sèze O, Toulemonde F. Doutremepuich C, et al. Among authors: de seze o. Semin Thromb Hemost. 1989 Oct;15(4):373-7. doi: 10.1055/s-2007-1002733. Semin Thromb Hemost. 1989. PMID: 2554497 No abstract available.

10

Could proteolytic enzyme modulate the interaction platelets/vessel wall in presence of ASA at ultra low doses?

Lalanne MC, de Seze O, Doutremepuich C, Belon P. Lalanne MC, et al. Among authors: de seze o. Thromb Res. 1991 Aug 15;63(4):419-26. doi: 10.1016/0049-3848(91)90228-o. Thromb Res. 1991. PMID: 1754994

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters